Emerging Stocks Down Under 19 January 2021: Clinuvel Pharmaceuticals, MyFiziq, MGC Pharmaceuticals

Clinuvel Pharmaceuticals: One for the vampires

In today's edition of Emerging Stocks Down Under, 2020 has not been kind to the shareholders of Clinuvel Pharmaceuticals, the Melbourne-based drug developer whose company-maker is Scenesse, for the treatment of porphyria. On 15 January 2020 the stock was going for over $29. It went below $14 during the Corona Crash and has only recovered to around $21 from there. We think Clinuvel stock will stall for a while yet until the company figures out just what its Next Big Thing is going to be.

Also in today's edition, a look at body measurement software developer MyFiziq (ASX: MYQ) and cannabis-based pharmaceutical developer MGC Pharmaceuticals (ASX: MXC).

Get access to all editions through a 30-day FREE TRIAL. No credit card required and the trial expires automatically.

GET A 30-DAY FREE TRIAL

Click here to read the previous edition of Emerging Stocks Down Under published 12 January 2021

For in-depth research reports or to keep up-to-date on the latest Stocks Down Under news see our parent company, Pitt Street Research, or follow us on Facebook and Twitter

Please register or upgrade your plan to access this content.

Save $$$
30-Day Free Trial
$0
No Credit Card Required!
Get access to 4 publications
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks
Profit Premium
$69
Get access to 4 publications
Access to the full research Archive
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks
30-Day Free Trial
$0
No Credit Card Required!
Get access to 4 publications
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks
Profit Premium
$59
BILLED ANNUALLY
Get access to 4 publications
Access to the full research Archive
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks